Galactokinase deficiency

Galactokinase deficiency
Classification and external resources
Galactitol
ICD-10	E74.2
ICD-9	271.1
OMIM	230200
DiseasesDB	29829
eMedicine	ped/815

Galactokinase deficiency, also known as Galactosemia type 2 or GALK deficiency, is marked by an accumulation of galactose and galactitol secondary to the decreased conversion of galactose to galactose-1-phosphate by galactokinase.^[1] The disorder is caused by mutations in the GALK1 gene, located on chromosome 17q24 (McKusick, Kniffin, 2006). Galactokinase catalyzes the first step of galactose phosphorylation in the Leloir pathway of intermediate metabolism. Galactokinase deficiency is one of the three inborn errors of metabolism that lead to hypergalactosemia. The disorder is inherited as an autosomal recessive trait. Unlike classic galactosemia, which is caused by deficiency of galactose-1-phosphate uridyltransferase, galactokinase deficiency does not present with severe manifestations in early infancy. Its major clinical symptom is the development of cataracts during the first weeks or months of life, as a result of the accumulation, in the lens, of galactitol, a product of an alternative route of galactose utilization. The development of early cataracts in homozygous affected infants is fully preventable through early diagnosis and treatment with a galactose-restricted diet. Some studies have suggested that, depending on milk consumption later in life, heterozygous carriers of galactokinase deficiency may be prone to presenile cataracts at 20–50 years of age (Kalaydjieva, et al. 1999).

Genetics

Galactokinase deficiency has autosomal recessive pattern of inheritance.

This is an autosomal recessive disorder,^[2] and unlike galactose-1-phosphate uridyltransferase deficiency, the symptoms are relatively mild. The only known symptom in affected children is the formation of cataracts, due to production of galactitol in the lens of the eye.^[3] Cataracts can present as a failure to develop a social smile and failure to visually track moving objects.

Gene Structure

The human GALK1 gene contains 8 exons and spans approximately 7.3 kb of genomic DNA. The GALK1 promoter was found to have many features in common with other housekeeping genes, including high GC content, several copies of the binding site for the Sp1 transcription factor and the absence of TATA-box and CCAAT-box motifs typically present in eukaryotic polymerase II promoters. Analysis by 5-prime-RACE PCR indicated that the GALK1 mRNA is heterogeneous at the 5-prime end, with transcription sites occurring at many locations between 21 and 61 bp upstream of the ATG start site of the coding region. In vitro translation experiments of the GALK1 cDNA indicated that the protein is cytosolic and not associated with endoplasmic reticulum membrane (Kalaydjieva, et al. 1999).

Treatment

Medical Care

   * Treatment may be provided on an outpatient basis.
   * Cataracts that do not regress or disappear with therapy may require hospitalization for surgical removal.

Surgical Care

   * Cataracts may require surgical removal.

Consultations

   * Biochemical geneticist
   * Nutritionist
   * Ophthalmologist

Diet

   * Diet is the foundation of therapy. Elimination of lactose and galactose sources suffices for definitive therapy.

Activity

   * No restriction is necessary.

(Roth MD, Karl S. 2009)

See also

• Galactosemia

References

This genetic disorder article is a stub. You can help Wikipedia by expanding it. v • d • e